Results 1 to 10 of about 2,241,192 (254)

Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis

BMC Gastroenterology, 2023
Background and aim In China, hepatorenal syndrome is a serious complication in the decompensated stage of hepatitis B cirrhosis, which requires early clinical intervention, so the early diagnosis of hepatorenal syndrome is crucial. This study establishes
Shouhao Wang, Zhewen Zhou, Chengan Xu, Hanzhu Chen, Wenya Ren, Xingdi Yang, Qiaoqiao Yin, Wei Zheng, Hongying Pan   +8 more
doaj   +2 more sources

Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment. [PDF]

Int J Mol Sci, 2023
Hepatorenal syndrome (HRS) is a disorder associated with cirrhosis and renal impairment, with portal hypertension as its major underlying cause. Moreover, HRS is the third most common cause of acute kidney injury, thus creating a major public health ...
Badura K, Frąk W, Hajdys J, Majchrowicz G, Młynarska E, Rysz J, Franczyk B.   +6 more
europepmc   +2 more sources

Role of renal Duplex ultrasonography in evaluation of hepatorenal syndrome

Egyptian Liver Journal, 2021
Background Hepatorenal syndrome is a potentially fatal complication of advanced liver disease. Markers for early diagnosis and identification of high-risk patients are lacking.
Mohamad Sherif Mogawer, Sahar Abdel Rahman Nassef, Samah Mohamad Abd Elhamid, Shaimaa Elkholy, Nahla Emad Abd El Aziz, Ula Mabid Al-Jarhi, Abeer Awad Abdellatif   +6 more
doaj   +2 more sources

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]

Liver Int
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC, Gordon F, Thuluvath PJ, Victor D, Kemmer N, Cardoza S, Jamil K, Frederick RT.   +7 more
europepmc   +2 more sources

Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial

Frontiers in Pharmacology, 2021
Background: Terlipressin is the first-line pharmacological treatment for hepatorenal syndrome. When terlipressin is unavailable, midodrine/octreotide or norepinephrine, with albumin, represent the alternative treatments. The comparative efficacy of these
Eman Ibrahim El-Desoki Mahmoud, Doaa H Abdelaziz, Doaa H Abdelaziz, Sherief Abd-Elsalam, Noha O. Mansour   +4 more
doaj   +2 more sources

Hepatorenal Syndrome: direct treatment costs and characteristics of patients admitted to intensive care [PDF]

Einstein (São Paulo)
Objective The purpose of this study was to describe the direct medical costs incurred in Brazil for the treatment of Hepatorenal Syndrome in intensive care and intermediate therapy care units, and to investigate the impact of this syndrome on patient ...
Franciele Robes Hortelã, Rodrigo Sfredo Kruger, Valéria Filomena de Oliveira, Hipolito Carraro Junior, Dominique Araújo Muzzillo, Sérgio Candido Kowalski   +5 more
doaj   +2 more sources

Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States

Medicines, 2021
Background: This study aimed to determine the rates of inpatient palliative care service use and assess the impact of palliative care service use on in-hospital treatments and resource utilization in hospital admissions for hepatorenal syndrome. Methods:
Charat Thongprayoon, Wisit Kaewput, Tananchai Petnak, Oisin A. O’Corragain, Boonphiphop Boonpheng, Tarun Bathini, Saraschandra Vallabhajosyula, Pattharawin Pattharanitima, Ploypin Lertjitbanjong, Fawad Qureshi, Wisit Cheungpasitporn   +10 more
doaj   +2 more sources

Treatment of hepatorenal syndrome [PDF]

Vojnosanitetski Pregled, 2007
Kezić Aleksandra, Mijač Dragana, Stojimirović Biljana   +2 more
doaj   +3 more sources

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies

Hepatology Communications, 2023
Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function.
M. Curry, H. Vargas, A. Befeler, N. Pyrsopoulos, V. Patwardhan, K. Jamil   +5 more
semanticscholar   +1 more source

Hepatorenal syndrome: Current concepts and future perspectives

Clinical and Molecular Hepatology, 2023
Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT).
C. Jung, J. Chang
semanticscholar   +1 more source